SI

Sulis Innovation

Europe, Bath and North East Somerset, United Kingdom, Bath

Description

Sulis Innovation is a U.K.-based venture capital firm that invests in seed stage companies.

Investor Profile

Sulis Innovation has made 4 investments, with 0 in the past 12 months and 25% as lead.

Stage Focus

  • Seed (50%)
  • Series C (25%)
  • Series Unknown (25%)

Country Focus

  • United Kingdom (75%)
  • United States (25%)

Industry Focus

  • Biotechnology
  • Health Care
  • Health Diagnostics
  • Security
  • Therapeutics
  • Medical Device
  • Medical
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Sulis Innovation frequently co-invest with?

YFM Equity Partners
Europe, England, United Kingdom, London
Co-Investments: 1
NV
Europe, England, United Kingdom, London
Co-Investments: 2
SV
Europe, England, United Kingdom, London
Co-Investments: 1
Quester Capital
Asia, Kuala Lumpur, Malaysia, Kuala Lumpur
Co-Investments: 2
BC
Europe, Wiltshire, United Kingdom, Swindon
Co-Investments: 1

What are some of recent deals done by Sulis Innovation?

Symetrica

Southampton, Southampton, United Kingdom

Symetrica develops and commercializes radiation detection and identification systems for various medical applications.

BiotechnologyHealth DiagnosticsSecurity
Series CMay 1, 2007
Amount Raised: $1,200,000
Micrima

Bristol, Bristol, City of, United Kingdom

Developing a breast imaging system using no ionising radiation, no breast compression and good in dense breasts. All issues for currently.

BiotechnologyHealth CareMedical Device
Series UnknownMar 8, 2006
Amount Raised: $824,846
Lectus Therapeutics

Cambridge, Cambridgeshire, United Kingdom

Lectus Therapeutics is a drug discovery and development company.

BiotechnologyHealth CareMedical
SeedNov 3, 2003
ProXara Biotechnology Ltd.

Bristol, Pennsylvania, United States

ProXara Biotechnology Ltd. operates as a biotechnology company.

BiotechnologyTherapeutics
SeedJan 1, 2002